ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: City of Hope launches Hematologic Malignancies and Stem Cell Transplantation Institute

October 31, 2014

Chop Analysis Shows Program Had Major Impact In Communities

January 25, 1985

In Setback For Generics, Court Overturns FDA.

November 9, 2001

Bristol-Myers, USDA Agreement n Yew Harvest Is Near; Agencies Plan Public Briefings On Taxol

June 14, 1991

In Brief: Eppley Is The “New” Center Getting an NCI Core; USC Appoints Jones Basic Science Chief

May 4, 1984

Post Reporter Responds To Criticism Of Cancer Series

January 1, 1982